Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of SNF472 Added to Background Care for Calciphylaxis
2018-001301-90Phase 3Unknown
- Sponsor
- Sanifit Therapeutics
- Start
- Mar 2020
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in calciphylaxis (CUA) comparing SNF472 + background care with Placebo + background care (2 arms). Primary endpoint: Primary efficacy endpoints (Part 1). Status: unknown.
02
Drugs
SNF472
03
Conditions
calciphylaxis (CUA)
Beyond the preview
Go deeper on 2018-001301-90.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001301-90.